Non-invasive Vagus Nerve Stimulation and Sleep in Healthy Volunteers.
NCT ID: NCT06928441
Last Updated: 2025-04-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
50 participants
INTERVENTIONAL
2025-04-30
2029-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Noninvasive Vagus Nerve Stimulation (VNS) for Neuromotor Adaptations
NCT03628976
Effect of Stimulation on the Vagus Nerve
NCT04206540
Transauricular Vagus Nerve Stimulation for Chronic Whiplash Associated Disorders
NCT07055373
Balance, Autonomic Response, and Sensory Modulation to Dosage of Mechanical Vagal Stimulation in Healthy Adults
NCT06541808
Transauricular Vagal Nerve Stimulation, Pressure Pain and Interoception
NCT06240026
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The battery-operated portable electro-stimulator (sham, or active) (Transcutaneous auricular vagal nerve stimulation) is designed to be attached to the outer ear. The Transcutaneous Electrical Nerve Stimulator (TENS) (Model WL-2103A): creates electrical impulses from a 9VDC-battery whose continuous intensity rate can be controlled by the user. The alligator clip with 2 electrodes is placed on the tragus part of the ear (shown to be 45% innervated via auricular vagus nerve) to stimulate the vagus nerve with an adjustable peak intensity (0-80mA), a frequency of 2 - 250Hz and a pulse width of 30-260 micro-sec. The vagus nerve contains a mixture of different types of nerve fibres, which are organized into bundles (fascicles). The fibres vary in diameter and conduction velocity, with A-type fibres the largest and fastest and C-type fibres the smallest and slowest, with B-type fibres intermediate. During nerve stimulation, fibres are activated in order of size from the largest (A-type) to the smallest (C-type). It has been suggested that A-type fibres are mainly activated during the stimulation via auricular vagus nerve. It has been shown that a decrease in sympathetic activity and increase of parasympathetic modulation of the heart (controlled by the vagus nerve) creates the transition from wake to sleep states. Thus, stimulating the vagus nerve may maintain a balance of the autonomic nervous system and therefore, affect the quality of sleep.
The self-instrumented sleep evaluation device is a polysomnography (PSG) level 2 + ECG Prodigy Sleep System consisting of a chest mounted unit (CMU) that records heart-rate (ECG), breathing-rate (nasal cannula), chest and stomach movements, and leg movements. The head mounted unit (HMU) measures electroencephalogram (EEG) of the frontal lobe, eye and chin movements. The wrist unit records blood oxygen saturation (SpO2) and pulse rate. All the wearable devices sends the specific data to the table-top tablet (TTU) via Bluetooth. The system uses secured web-based PSG to analyze the EEG, electrooculogram (EOC), ECG, electromyogram, accelerometry, acoustic signals, nasal airflow, thoracic and abdomen respiratory effect, pulse rate and oxy-hemoglobin saturation. All results are scored using Michele Sleep Scoring System to create necessary files showing all the stages of sleep (N1, N2, N3, REM) including sleep length, desaturation and efficiency.
40-50 Participants will be asked to attend five study visits over a 1-2 month period:
1. Laboratory visit 1: Informed consent, screening (\~ 1 hour)
2. Laboratory visit 2: Assessment of neuromodulation stimulation level using the lab stimulation device and demonstration of how-to self-instrument the Cerebra Sleep monitoring kit at their personal residence for 4 nights consecutively. Participants will be assigned to either a sham, or active stim device to self-administer and given the sleep questionnaires for each night. (\~ 2 hours)
3. Laboratory visit 3: Return the equipment and questionnaires and de-brief on the past 4 nights (\~ 30 mins)
4. Laboratory visit 4: (after 21-day washout period): Re-assessment of neuromodulation stimulation level and re-issue of a sleep kit. (\~ 2 hours)
5. Laboratory visit 5: Return the equipment and debrief on the past 4 nights. (\~30 mins)
During the laboratory visits, participants will be trained on how to complete a full self-instrumentation using the sleep unit. For the ear neuro-stimulator, participants will respond to the tester's prompts as they experience increases in the level of stimulation. Participants will then be chosen at random to receive either the 30 minutes of outer ear stimulation, or no stimulation since the final setting of the neuro-stimulator will not be observable.
The analysis will be conducted using a two-tailed, two sample t-test on the first intervention to determine there were no significant differences within the 2 groups (sham, or active). T-test for differences between the two groups.
All the sleep data will be encrypted and transferred to a secure database and all hard copied data will be separated from identifiers into a locked file storage system.
Once the study is finished, the participants will have the option to view individual results.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Trial Arm 1
Participants and experimenters are blinded. The aim of this study is to determine whether a battery-operated portable device (current adjustable) attached to the outer ears (tragus) makes one more likely to improve on their sleep and quality of daily life. Investigators believe this device encourages increases in vagal tone associated with increases in baroreflex sensitivity, improving sleep and possibly leading to an increase in quality of life.
Transcutaneous Pulsed Electrical Stimulation (Device: WL-2103A)
The Transcutaneous Electrical Nerve Stimulator (TENS) creates electrical impulses from a 9VDC-battery whose continuous intensity rate can be controlled by the user. The alligator clip with 2 electrodes is placed on the tragus part of the ear (shown to be 45% innervated via auricular vagus nerve) to stimulate the vagus nerve with an adjustable peak intensity (0-80mA), a frequency of 2 - 250Hz and a pulse width of 30-260 µsec. The vagus nerve contains a mixture of different types of nerve fibres, which are organized into bundles (fascicles). The fibres vary in diameter and conduction velocity, with A-type fibres the largest and fastest and C-type fibres the smallest and slowest, with B-type fibres intermediate. During nerve stimulation, fibres are activated in order of size from the largest (A-type) to the smallest (C-type). It has been suggested that A-type fibres are mainly activated during the stimulation via auricular vagus nerve.
Trial Arm 2
Participants and experimenters are blinded. The aim of this study is to determine whether a battery-operated portable device (current adjustable) attached to the outer ears (tragus) makes one more likely to improve on their sleep and quality of daily life. Investigators believe this device encourages increases in vagal tone associated with increases in baroreflex sensitivity, improving sleep and possibly leading to an increase in quality of life.
Transcutaneous Pulsed Electrical Stimulation (Device: WL-2103A)
The Transcutaneous Electrical Nerve Stimulator (TENS) creates electrical impulses from a 9VDC-battery whose continuous intensity rate can be controlled by the user. The alligator clip with 2 electrodes is placed on the tragus part of the ear (shown to be 45% innervated via auricular vagus nerve) to stimulate the vagus nerve with an adjustable peak intensity (0-80mA), a frequency of 2 - 250Hz and a pulse width of 30-260 µsec. The vagus nerve contains a mixture of different types of nerve fibres, which are organized into bundles (fascicles). The fibres vary in diameter and conduction velocity, with A-type fibres the largest and fastest and C-type fibres the smallest and slowest, with B-type fibres intermediate. During nerve stimulation, fibres are activated in order of size from the largest (A-type) to the smallest (C-type). It has been suggested that A-type fibres are mainly activated during the stimulation via auricular vagus nerve.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transcutaneous Pulsed Electrical Stimulation (Device: WL-2103A)
The Transcutaneous Electrical Nerve Stimulator (TENS) creates electrical impulses from a 9VDC-battery whose continuous intensity rate can be controlled by the user. The alligator clip with 2 electrodes is placed on the tragus part of the ear (shown to be 45% innervated via auricular vagus nerve) to stimulate the vagus nerve with an adjustable peak intensity (0-80mA), a frequency of 2 - 250Hz and a pulse width of 30-260 µsec. The vagus nerve contains a mixture of different types of nerve fibres, which are organized into bundles (fascicles). The fibres vary in diameter and conduction velocity, with A-type fibres the largest and fastest and C-type fibres the smallest and slowest, with B-type fibres intermediate. During nerve stimulation, fibres are activated in order of size from the largest (A-type) to the smallest (C-type). It has been suggested that A-type fibres are mainly activated during the stimulation via auricular vagus nerve.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* In good health with no evidence of medical problems.
* Ability to provide informed consent and willingness to comply with the study procedures.
* Ability to use a battery operated electro-stimulating device attached to your ears for 30 minutes.
* Ability to breathe through the nose comfortably and wear a sleep monitoring device.
Exclusion Criteria
* Known history of heart, lung, kidney, or liver disease.
* Diagnosis of asthma or sleep apnea.
* Diagnosis of diabetes.
* Current smoker.
* Pregnancy or lactation due to the location of the sleep devices.
* Resting heart rate \> 120 bpm.
* Systolic BP \> 150, diastolic BP \> 90.
* Presence of any other condition that, in the opinion of the PI, makes the individual unsuitable for participation.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Natural Sciences and Engineering Research Council, Canada
OTHER
University of Calgary
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Unviersity of Calgary
Calgary, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REB24-1438
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.